Nifurtimox ( DrugBank: Nifurtimox )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 6 |
65. Primary immunodeficiency
Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02369978 (ClinicalTrials.gov) | August 2015 | 17/2/2015 | CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) | Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis) | Chagas Disease | Drug: Nifurtimox;Drug: Benznidazole;Drug: Placebo | Universidad Autónoma de Bucaramanga | Fundación Cardioinfantil Instituto de Cardiología;Instituto Nacional de Salud (Colombia);Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben | Recruiting | 20 Years | 55 Years | All | 500 | Phase 2/Phase 3 | Colombia |
| 2 | NCT01685827 (ClinicalTrials.gov) | October 2012 | 12/9/2012 | Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 | Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study | Human African Trypanosomiasis (HAT);Sleeping Sickness | Drug: Fexinidazole;Drug: Nifurtimox;Drug: Eflornithine | Drugs for Neglected Diseases | NULL | Completed | 15 Years | N/A | All | 394 | Phase 2/Phase 3 | Central African Republic;Congo, The Democratic Republic of the;Congo |
| 3 | NCT00906880 (ClinicalTrials.gov) | April 2009 | 19/5/2009 | Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase | Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Stage | Human African Trypanosomiasis | Drug: Nifurtimox-Eflronithine Combination Treatment (NECT) | Drugs for Neglected Diseases | Ministry of Public Health, Democratic Republic of the Congo;Swiss Tropical & Public Health Institute | Completed | N/A | N/A | Both | 630 | Phase 4 | Congo |
| 4 | NCT00146627 (ClinicalTrials.gov) | September 2004 | 6/9/2005 | Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis | Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase | Trypanosomiasis, African | Drug: Eflornithine;Drug: Nifurtimox | Drugs for Neglected Diseases | Medecins Sans Frontieres, Netherlands;PNLTHA-DRC;;PNLTHA-RoC;Epicentre;Swiss Tropical & Public Health Institute;World Health Organization;Medecins Sans Frontieres, Netherlands;PNLTHA-DRC;;PNLTHA-RoC;Epicentre;Swiss Tropical & Public Health Institute;World Health Organization | Completed | 15 Years | 70 Years | Both | 280 | Phase 3 | Congo, The Democratic Republic of the;Congo;The Democratic Republic of the Congo;Uganda |
| 5 | NCT00489658 (ClinicalTrials.gov) | October 2002 | 20/6/2007 | Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda | Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda | Trypanosomiasis, African | Drug: Eflornithine plus Nifurtimox combination therapy | Epicentre | Medecins Sans Frontieres | Terminated | N/A | N/A | Both | 31 | Phase 2/Phase 3 | Uganda |
| 6 | NCT00330148 (ClinicalTrials.gov) | March 2001 | 24/5/2006 | Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis | Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase | Trypanosomiasis, African | Drug: melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;Drug: melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;Drug: nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d | Epicentre | Medecins Sans Frontieres;Embassy of France in Uganda;National Sleeping Sickness Control Program, Uganda | Terminated | N/A | N/A | Both | 435 | Phase 3 | Uganda |